DK2137202T3 - Fremgangsmåde til syntese af ib-meca - Google Patents

Fremgangsmåde til syntese af ib-meca Download PDF

Info

Publication number
DK2137202T3
DK2137202T3 DK08719985.7T DK08719985T DK2137202T3 DK 2137202 T3 DK2137202 T3 DK 2137202T3 DK 08719985 T DK08719985 T DK 08719985T DK 2137202 T3 DK2137202 T3 DK 2137202T3
Authority
DK
Denmark
Prior art keywords
meca
vol
formula
diol
acetonide
Prior art date
Application number
DK08719985.7T
Other languages
English (en)
Inventor
Paul Bruzinski
Cameron Gibb
Pedro Hernandez-Abad
Xuejun Liu
Original Assignee
Can-Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can-Fite Biopharma Ltd filed Critical Can-Fite Biopharma Ltd
Application granted granted Critical
Publication of DK2137202T3 publication Critical patent/DK2137202T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (12)

  1. FREMGANGSMÅDE TIL SYNTESE AF IB-MECA
    1. Fremgangsmåde til den kemiske syntese af IB-MECA med følgende formel (I):
    (I) hvilken fremgangsmåde omfatter: (i) omsætning af 6-halopurin-9-ribosid med følgende formel (II):
    hvor X er et halogen, der er udvalgt fra gruppen bestående af Cl, I og Br; med et diolbeskyttende reagens for at opnå et diolbeskyttet 6-halopurin med følgende formel (III):
    (ITT) hvor det diolbeskyttende reagens omfatter en lige eller forgrenet CrC6-alkylgruppe; (ii) oxidering af den primære alkohol i det diolbeskyttede 6-halopurin med formlen (III) ved tilsætning af en katalytisk mængde af et oxideringsmiddel bestående af natriumperiodat og rutheniumtrichlorid (RuCl3) for at opnå et tilsvarende carboxylsyrederivat med formlen (IV):
    (TV) isolering af derivatet ved krystallisering fra vand/acetonitril; (iii) omsætning af carboxylsyregruppcn af derivatet med formlen (IV) med et halogcncringsmiddd SOCl2 i acetonitril for at opnå et syrechlorid efterfulgt af omsætning med methylamin i nærvær af diisopropyletfrylamin (DIPEA) for at opnå det tilsvarende methylamidderivat af det diolbeskyttede 6-halopurin (III), hvor methylamidderivatet har formlen (V):
    (V) substitution af halogengruppen af methylamidderivat (V) med 3-iodbenzylamin med < 0,5 % af 3-brombenzylaminhydrochlorid, i nærvær af DIPEA, reaktionsblandingen opvarmes til 70 °C. (iv) for at danne en diolbeskyttet IB-MECA med formlen (VI);
    (VI) og for at muliggøre, at den diolbeskyttede IB-MECA med formlen (VI) rekrystalliserer i en MeOH; (v) fjernelse af diolbcskyttclsc i nærvær af vandig saltsyre for at opnå IB-MECA med formlen (I) ved et renhedsniveau på 99,67 % og 90 % udbytte.
  2. 2. Fremgangsmåde ifølge krav 1, hvor halogenet er chlorid.
  3. 3. Fremgangsmåde ifølge krav 1 eller 2, hvor beskyttelsesgruppen er C3-C6-dialkyloxyalkan.
  4. 4. Fremgangsmåde ifølge krav 3, hvor dialkyloxyalkanen er 2,2-dimethoxypropan.
  5. 5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor diolbeskyttelsen opnås i nærvær af en kraftig syre og et polært organisk opløsningsmiddel.
  6. 6. Fremgangsmåde ifølge krav 5, hvor den kraftige syre er udvalgt fra p-TsOH, methansulfonsyre, benzensulfonsyre, myresyre, saltsyre, svovlsyre.
  7. 7. Fremgangsmåde ifølge krav 5, hvor det polære organiske opløsningsmiddel er et vandblandbart opløsningsmiddel.
  8. 8. Fremgangsmåde ifølge krav 7, hvor det polære organiske opløsningsmiddel er acetone.
  9. 9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 8, hvor oxideringen sker i nærvær af en katalytisk mængde af en blanding af RuC13 og natriumperiodat.
  10. 10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor 3-iodbenzylaminhydrochloridet tilvejebringes efter rekrystallisering fra et protisk opløsningsmiddel.
  11. 11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, hvor fjernelsen af diolbeskyttelsesgruppen sker i nærvær af en kraftig syre og et polært, ikke-protisk opløsningsmiddel.
  12. 12. Fremgangsmåde ifølge krav 11, hvor den kraftige syre er HC1 og opløsningsmidlet er tetrahydrofuran (THF).
DK08719985.7T 2007-03-14 2008-03-13 Fremgangsmåde til syntese af ib-meca DK2137202T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90683807P 2007-03-14 2007-03-14
PCT/IL2008/000360 WO2008111082A1 (en) 2007-03-14 2008-03-13 Process for the synthesis of ib-meca

Publications (1)

Publication Number Publication Date
DK2137202T3 true DK2137202T3 (da) 2017-10-02

Family

ID=39530638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08719985.7T DK2137202T3 (da) 2007-03-14 2008-03-13 Fremgangsmåde til syntese af ib-meca

Country Status (10)

Country Link
US (1) US9102698B2 (da)
EP (1) EP2137202B1 (da)
JP (1) JP5467872B2 (da)
CN (1) CN101646685B (da)
DK (1) DK2137202T3 (da)
ES (1) ES2641190T3 (da)
HU (1) HUE034474T2 (da)
PL (1) PL2137202T3 (da)
PT (1) PT2137202T (da)
WO (1) WO2008111082A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105388A1 (zh) * 2017-11-29 2019-06-06 苏州科睿思制药有限公司 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
CN110003211A (zh) * 2019-05-06 2019-07-12 江苏联昇化学有限公司 一种抗癌药物cf-102的合成新工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4930392A (da) 1972-07-18 1974-03-18
DE2244328A1 (de) 1972-09-09 1974-03-21 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE69428536T2 (de) * 1993-07-13 2002-06-06 Nasa A3 -adenosin -rezeptor agonisten
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
AU2003274648A1 (en) 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
AU2003282359A1 (en) 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
CA2513545A1 (en) * 2003-01-17 2004-08-05 Ajinomoto Co., Inc. Processes for production of nucleosides
FI115172B (fi) 2003-07-24 2005-03-15 Filtronic Lk Oy Antennijärjestely ulkoisen laitteen liittämiseksi radiolaitteeseen
EP1699459B1 (en) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
EP1778239B1 (en) 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
KR20070085839A (ko) 2004-11-08 2007-08-27 캔-파이트 바이오파마 리미티드 가속 골 흡수의 치료 방법
MX2007006500A (es) 2004-12-02 2007-07-13 Can Fite Biopharma Ltd Tratamiento de inflamacion.
US20080300213A1 (en) 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
JP5185139B2 (ja) 2006-01-27 2013-04-17 キャン−ファイト・バイオファーマ・リミテッド ドライアイ疾患治療用アデノシンa3レセプターアゴニスト

Also Published As

Publication number Publication date
ES2641190T3 (es) 2017-11-08
US20100087636A1 (en) 2010-04-08
PL2137202T3 (pl) 2017-12-29
PT2137202T (pt) 2017-10-02
EP2137202B1 (en) 2017-06-21
US9102698B2 (en) 2015-08-11
JP5467872B2 (ja) 2014-04-09
CN101646685B (zh) 2014-12-17
CN101646685A (zh) 2010-02-10
WO2008111082A1 (en) 2008-09-18
EP2137202A1 (en) 2009-12-30
HUE034474T2 (en) 2018-02-28
JP2010521452A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
KR102532498B1 (ko) 젬시타빈-포스페이트 부분입체이성질체의 분리 방법
EP3150600A1 (en) Dihydropyrimido loop derivative as hbv inhibitor
EP4289823A1 (en) Substituted pyridazine phenol derivatives
JPH0637394B2 (ja) 腫瘍治療剤
JPH0723394B2 (ja) 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US7371737B2 (en) 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity
EP2341772B1 (en) Synthesis of decitabine
DK2137202T3 (da) Fremgangsmåde til syntese af ib-meca
JP2009541436A (ja) 治療用化合物
KR20070073958A (ko) 디플루오로뉴클레오시드 및 이의 제조 방법
JP2023011699A (ja) 3位置換5-アミノ-6H-チアゾロ[4,5-d]ピリミジン-2,7-ジオン化合物の製造法
EP0749969A2 (en) d4T polymorphic form I process
US7671191B2 (en) Methods for preparing 2-alkynyladenosine derivatives
WO1992019638A1 (fr) DERIVE DE 1-β-D-ARABINOFURANOSYL-(E)-5-(2-HALOGENOVINYL)-URACILE
CN113004202B (zh) 一种高纯度托伐普坦的制备方法
WO2022124410A1 (ja) シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法
JP2009541437A (ja) 治療用化合物
JP2004502780A (ja) アデノシン化合物及びそれを含む医薬組成物
Lerner Preparation of the E and Z isomers of 9-(5, 6-dideoxy-. beta.-D-erythro-hex-4-enofuranosyl) adenine
JP3025541B2 (ja) 2−置換アデノシン誘導体および循環器疾患用薬
CN112521405A (zh) 一种培美曲塞二钠杂质化合物
JP5616355B2 (ja) モルフィン−6−グルクロニドの2環式誘導体、この調製方法および治療法でのこの使用
JP2509140B2 (ja) アデノシン誘導体を有効成分として含有する医薬組成物
EP2891660A1 (en) Process for the preparation of cladribine
JPS62240622A (ja) 抗腫瘍剤